News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 702 results
August 2024
-
SR 1
-
Reference Validation
-
Reference 1
-
Content synch validation - end to end
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus
-
Featured News
Download Card in Featured News
-
Media Release
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs.… -
Alt title check
Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.
-
Lorem Ipsum
-
Featured News
Dummy Featured News
-
Story Testing with Disclaimer field
Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.
July 2024
-
Media Release
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Priority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard… -
A Journey of Compassion: From Pharmacy to Oncology Sales
Novartis employee story journey into Oncology sales
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 59
- › Next page